Shareholder Alert: Sohmer Law Firm Investigating Revance Therapeutics, Inc.

BLOOMFIELD, N.J.--()--The Sohmer Law Firm announces that it is investigating possible breaches of fiduciary duty claims by the board of directors of Revance Therapeutics, Inc. (NASDAQ:RVNC).

A class action lawsuit was filed against the company alleging that the Registration Statement issued in connection with the company’s June 19, 2014 follow-on public stock offering failed to disclose, among other things, that Revance: (i) had not commenced a Phase 3 clinical trial of RT0001—its lead product under development for the treatment of wrinkles around the eyes—in the first quarter of 2014; and, (ii) did not have the quality or quantity of RT001 to complete a Phase 3 clinical trial. The Sohmer Law Firm is investigating certain claims the company and its shareholders may have against those who signed the Registration Statement.

If you are a current Revance shareholder and want to discuss your legal rights, at no cost and without obligation, please contact Stephen Sohmer by telephone at (973) 337-6894 or by e-mail at SohmerLaw@gmail.com.

ATTORNEY ADVERTISING. Prior results do not guarantee a similar outcome.

Contacts

The Sohmer Law Firm
Stephen Sohmer, 973-337-6894
SohmerLaw@gmail.com

Release Summary

The Sohmer Law Firm announces that it is investigating possible breaches of fiduciary duty claims by the board of directors of Revance Therapeutics, Inc. (NASDAQ:RVNC).

The Sohmer Law Firm